Viatris Reports Positive Outcomes from Phase 3 LYNX-2 Trial of MR-142 for Night Driving Impairments

Viatris Reports Promising Results for MR-142 in Treating Night Driving Impairments



Viatris Inc., a leading global healthcare company, recently disclosed the encouraging top-line results from its pivotal Phase 3 trial known as LYNX-2. This initiative primarily evaluates the safety and efficacy of MR-142, a phentolamine ophthalmic solution, in alleviating significant chronic night driving impairment in keratorefractive patients undergoing conditions of reduced mesopic vision. The results represent a significant advancement in addressing a critical unmet need, especially in patients who struggle with visual disturbances under low-light conditions.

Overview of the LYNX-2 Trial



Conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration, the LYNX-2 trial involved a rigorously designed, randomized, double-masked study comprising 199 patients. Participants were randomly allocated to receive either MR-142 or a placebo for six weeks, with the treatment applied nightly to both eyes. The primary endpoint was defined as the achievement of a ≥15-letter gain in Mesopic Low Contrast Distance Visual Acuity (mLCVA) on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Day 15.

The findings revealed that significantly more patients in the MR-142 group met this primary endpoint compared to those receiving the placebo, marking a notable statistical significance (p<0.05). Furthermore, patients reported a functional benefit concerning difficulties caused by oncoming headlights and glare, greatly contributing to the credibility of MR-142 as a treatment option.

No Evidence of Tachyphylaxis



An important aspect of the study is that no evidence of tachyphylaxis—an acute desensitization to a drug—was observed throughout the entire six-week observation period. This finding strengthens the argument for MR-142’s long-term efficacy as it suggests consistent performance without diminishing effects.

Insights from Viatris Leadership



Viatris Chief Research and Development Officer, Philippe Martin, emphasized the goal of the company’s eye care pipeline: to provide solutions to a variety of ophthalmic conditions. He articulated the belief that the promising results confirm MR-142's potential to address significant challenges faced by keratorefractive patients, specifically regarding visual impairments while driving at night.

Corinne Le Goff, Viatris Chief Commercial Officer, also expressed excitement regarding MR-142, noting that the positive results from this Phase 3 trial mark a pivotal step in their ongoing commitment to enhancing eye and vision health on a global scale. Viatris aims to utilize its established infrastructure in eye care to expand its product offerings effectively to meet patient needs.

FDA Fast Track Designation



In a move that underscores the urgency and necessity for such therapies, the FDA has granted Fast Track designation to MR-142. This status can expedite the development and review of new treatments intended for serious conditions with unmet needs, making the path to availability for patients more accessible. Specifically, MR-142 is being developed to combat night driving impairment while reducing the risk of motor vehicle accidents linked to visual disturbances.

Future Studies and Beyond



Looking ahead, a second pivotal study, LYNX-3, is expected to commence soon with results anticipated in the first half of 2026. This ongoing commitment from Viatris to evaluating MR-142’s efficacy further establishes the company as a key player in developing solutions tailored to modern ocular health challenges.

The urgent need for adequate treatment options is highlighted by the estimated prevalence of Night Vision Disturbance (NVD) across major markets, reaching nearly 55 million individuals in 2023, with the U.S. alone accounting for roughly 45% of these cases.

Conclusion



Viatris continues to identify and bridge gaps in treatment availability, and the promising outcomes of the LYNX-2 trial reaffirm MR-142’s potential as a first-in-class treatment. With an aspiration to enhance the quality of life for patients facing visual difficulties, Viatris remains committed to bringing innovative solutions to the forefront of eye care. In a space where there are currently no FDA-approved options for the visual disturbances caused by night driving, MR-142 emerges as a beacon of hope for many.

For more details about the trial's design and progress, further information can be found at ClinicalTrials.gov under the identifier NCT06349759.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.